Werewolf Therapeutics Q4 EPS $(0.33) Beats $(0.43) Estimate, Sales $1.50M Miss $1.94M Estimate
Werewolf Therapeutics Q4 EPS $(0.33) Beats $(0.43) Estimate, Sales $1.50M Miss $1.94M Estimate
Werewolf Therapeutics第四季度每股收益美元（0.33美元）超过预期（0.43美元），销售额为150万美元，低于194万美元的预期
Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.43) by 23.26 percent. This is a 15.38 percent increase over losses of $(0.39) per share from the same period last year. The company reported quarterly sales of $1.50 million which missed the analyst consensus estimate of $1.94 million by 22.63 percent. This is a 79.39 percent decrease over sales of $7.28 million the same period last year.
Werewolf Therapeutics（纳斯达克股票代码：HOWL）公布的季度亏损为每股0.33美元，比分析师普遍预期的0.43美元（0.43美元）高出23.26％。这比去年同期每股亏损0.39美元（0.39美元）增长了15.38％。该公司公布的季度销售额为150万美元，比分析师普遍预期的194万美元低22.63％。这比去年同期的728万美元销售额下降了79.39％。